TELA Bio downgraded by Piper Sandler with a new price target
$TELA
Medical/Dental Instruments
Health Care
Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $5.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 5/31/2022 | $17.00 | Buy | Lake Street |
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)
SC 13G - TELA Bio, Inc. (0001561921) (Subject)
SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)
Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously
Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l
MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
8-K - TELA Bio, Inc. (0001561921) (Filer)
8-K - TELA Bio, Inc. (0001561921) (Filer)
SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)
MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. This milestone follows the successful U.S. launch of OviTex Inguinal in 2024, where it has achieved over $1 million in sales in its first year and has seen growing adoption by surgeons seeking a tailored, more natural alternative to synthetic mesh for inguinal hernia procedures. OviTex Inguinal is av
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l
MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA's management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the
MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme
MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the
MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r